Laser Neurolysis (Laser Peripheral Nerve Block)
Customize your policy alerts
Sign up for Aetna Policy 0552 alerts
Get alerted when Policy 0552 changes without checking for updates manually.
Monitor payer policy activity
This policy governs Aetna's coverage stance on laser neurolysis (noninvasive laser application to peripheral nerves) and lists indications considered experimental, investigational, or unproven. It affects providers seeking coverage for laser neurolysis procedures for members.
No material clinical or coverage changes in this revision.
Coverage Determinations
Experimental, Investigational, or Unproven
Aetna considers laser peripheral nerve block (laser neurolysis) experimental, investigational, or unproven for the following indications (not an all‑inclusive list):
These indications are examples given in the policy; the list is not all-inclusive.
Aetna considers laser peripheral nerve block (laser neurolysis) experimental, investigational, or unproven because there is insufficient evidence regarding its effectiveness for the indications listed. The policy specifically identifies examples where evidence is limited or lacking — including carpal tunnel syndrome, complex regional pain syndrome (CRPS), facet joint pain, phantom limb pain, and sacroiliac joint pain — and therefore does not support routine coverage for these uses.
Certain ICD-10 diagnosis codes are identified as not covered when used to support claims for the indications listed in this Clinical Policy Bulletin. Examples of such codes include codes for phantom limb syndrome with pain (G54.6), carpal tunnel syndrome (G56.00–G56.03), causalgia/CRPS II (G56.40–G56.42; G57.70–G57.73), CRPS I (G90.50–G90.59), and sacroiliac joint pain (M53.3). Providers should reference the policy’s listed ICD-10 codes when preparing authorization requests or claims submissions.
Relevant Procedure and Diagnosis Codes
| 64600 - 64610 | Destruction by neurolytic agent, trigeminal nerve |
| 64620 - 64640 | Destruction by neurolytic agent, intercostal nerve, paravertebral facet joint nerve, or pudendal nerve |
| 64702 - 64704 | Neuroplasty, digital, one or both, same digit or nerve of hand or foot |
| 64708 - 64714 | Neuroplasty, major peripheral nerve, arm or leg, open |
| 64727 | Internal neurolysis, requiring the use of operating microscope (List separately in addition to code for neuroplasty) |
| G54.6 | Phantom limb syndrome with pain |
| G56.00 - G56.03 | Carpal tunnel syndrome |
| G56.40 - G56.42 | Causalgia of upper limb [Complex regional pain syndrome II of upper limb] |
| G57.70 - G57.73 | Causalgia of lower limb [Complex regional pain syndrome II of lower limb] |
| G90.50 - G90.59 | Complex regional pain syndrome I (CRPS I) [Complex regional pain syndrome I of upper and lower limb] |
| M53.0 | Cervicocranial syndrome |
| M53.3 | Sacrococcygeal disorders, not elsewhere classified [sacroiliac joint pain] |
| M53.82 - M53.83 | Other specified dorsopathies cervical and cervicothoracic region |
| M54.2 | Cervicalgia |
| M54.50 - M54.59 | Low back pain |
Provider Requirements and Billing Notes
Include listed CPT/HCPCS and ICD-10 codes with authorization/claims
When seeking authorization or submitting claims, include the procedure (CPT/HCPCS) and diagnosis (ICD-10) codes listed in the policy. Relevant procedure codes include 64600–64610; 64620–64640; 64702–64704; 64708–64714; and 64727. The policy also lists specific ICD-10 diagnosis codes that are not covered for the indications in this bulletin (see ICD-10 group).
- CPT/HCPCS procedure codes: 64600-64610; 64620-64640; 64702-64704; 64708-64714; 64727
- ICD-10 diagnosis codes identified as not covered: G54.6; G56.00–G56.03; G56.40–G56.42; G57.70–G57.73; G90.50–G90.59; M53.0; M53.3; M53.82–M53.83; M54.2; M54.50–M54.59; M54.6
Require trial of conservative/established therapies before experimental laser neurolysis
The policy notes limited and low-quality evidence for laser therapy and references systematic review evidence (Cochrane) for CRPS physiotherapy; established conservative therapies such as physiotherapy, graded motor imagery, and mirror therapy are the preferred, evaluated approaches before considering experimental treatments like laser neurolysis.
- Cochrane review (Smart et al.) found low or very low quality evidence for physiotherapy interventions in CRPS (18 RCTs; 739 participants).
- Aetna considers laser neurolysis experimental, investigational, or unproven for listed indications, implying conservative/established therapies should be tried first.
Coding and documentation reminders for neurolytic/neuroplasty procedures
Document and code neurolytic/neuroplasty procedures precisely and note the policy’s ICD-10 exclusions; include the specific CPT codes for neurolysis/neuroplasty and use diagnosis codes consistent with the member’s condition but avoid ICD-10 codes the policy identifies as not covered for these indications.
- Use procedure codes 64600–64610; 64620–64640; 64702–64704; 64708–64714; 64727 for neurolytic and neuroplasty procedures as applicable.
- Do not report ICD-10 codes listed as not covered (see policy list) when seeking coverage for laser neurolysis for the listed indications.
Denial risk: listed indications are considered experimental/investigational
Claims for laser peripheral nerve block (laser neurolysis) for the indications listed in this policy are considered experimental, investigational, or unproven and may be denied on that basis.
- Listed example indications at risk for denial include: carpal tunnel syndrome; complex regional pain syndrome; facet joint pain; phantom limb pain; sacroiliac joint pain.
Preference for Conservative or Established Therapies
Conservative Treatment Requirements
Implied preference for conservative or established therapies before considering experimental interventions such as laser neurolysis:
This policy references systematic review evidence indicating limited and low‑quality data for physiotherapy interventions overall and small/low‑quality evidence for laser therapy; therefore conservative treatments are the standard approaches evaluated in reviews.
Imaging / Procedural Requirements
No imaging requirement specified for laser neurolysis
No imaging or fluoroscopic guidance requirement is specified for laser denervation / laser neurolysis in this policy; studies cited describe targeting anatomy (e.g., dorsal facet capsule) but do not mandate imaging.
- Policy states imaging requirements for laser neurolysis: none specified.
Background
Laser neurolysis refers to the noninvasive application of laser to peripheral nerves and is considered a form of low‑level laser therapy. It has primarily been investigated in small, uncontrolled studies for conditions such as carpal tunnel syndrome and facet joint denervation; overall, the available studies are limited by small sample sizes, short follow‑up, and lack of rigorous controls, contributing to the policy’s conclusion that effectiveness is not established.
Definitions
Not Covered Indications
NOT COVERED: Laser peripheral nerve block (laser neurolysis) is not covered for the listed indications, including but not limited to carpal tunnel syndrome, complex regional pain syndrome (CRPS), facet joint pain, phantom limb pain, and sacroiliac joint pain. Claims submitted for these indications may be denied as the procedure is considered experimental, investigational, or unproven; providers should also note the policy’s list of ICD-10 diagnosis codes that are not covered when submitting claims.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.